Echocardiographic and survival studies in mice undergoing endotoxic shock: Effects of genetic ablation of inducible nitric oxide synthase and pharmacologic antagonism of platelet-activating factor

Journal of Surgical Research

Volumn 86, Issue 2, 1999, Pages 198-205

  Nicholson, Susan C ^a   Hahn, Rebecca T ^a   Grobmyer, Stephen R ^a   Brause, Juliet E ^a   Hafner, Alice ^a   Potter, Strite ^a   Devereux, Richard B ^a   Nathan, Carl F ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Echocardiography; Hemodynamic; Lipopolysaccharide; P. acnes; Septic shock

Indexed keywords

L 691880; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEMODYNAMICS; IMMUNOMODULATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEPTIC SHOCK; SURVIVAL;

EID: 0032703474     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1999.5715     Document Type: Article

References (34)

1. Parrillo, J. E. Pathogenetic mechanisms of septic shock. N. Engl. J. Med. 328: 1471, 1993.
2. Zhou, M., Wang, P., and Chaudry, I. H. Cardiac contractility and structure are not significantly compromised even during the late, hypodynamic stages of sepsis. Shock 9: 352, 1998.
3. Kumar, A., Thota, V., Dee, L., Olson, J., Uretz, E., and Parillo, J. E. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J. Exp. Med. 183: 949, 1996.
4. Balligand, J. L., Kelly, R. A., Marsden, P. A., Smith, T. W., and Michel, T. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc. Natl. Acad. Sci. USA 90: 347, 1993.
5. Finkel, M. S., Oddis, C. V., Jacob, T. D., Watkins, S. C., Hattler, B. G., and Simmons, R. L. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257: 387, 1992.
6. MacMicking, J. D., Nathan, C., Hom, G., Chartrain, N., Fletcher, D. S., Trumbauer, M., Stevens, K., Xie, Q. W., Sokol, K., Hutchinson, N., Chen, H., and Mudgett, J. S. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 81: 641, 1995.
7. Cobb, J. P., and Danner, R. L. Nitric oxide and septic shock. JAMA 275: 1192, 1996.
8. Szabo, C. The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury. Shock 6: 79, 1996.
9. Harbrecht, B. G., Billiar, T. R., Stadler, J., Demetris, A. J., Ochoa, J., Curran, R. D., and Simmons, R. L. Inhibition of nitric oxide synthesis during endotoxemia promotes intrahepatic thrombosis and an oxygen radical-mediated hepatic injury. J. Leukocyte Biol. 52: 390, 1992.
10. MacMicking, J., Xie, Q. W., and Nathan, C. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15: 323, 1997.
11. Shiloh, M. U., MacMicking, J., Nicholson, S., Brause, J., Potter, S., Fang, F., Marino, M., Dinauer, M., and Nathan, C. Phenotype of mice and macrophages deficient in both phagocyte oxidase and inducible nitric oxide synthase. Immunity 10: 29, 1999.
12. de Belder, A. J., Radomski, M. W., Why, H. J., Richardson, P. J., Bucknall, C. A., Salas, E., Martin, J. F., and Moncada, S. Nitric oxide synthase activities in human myocardium. Lancet 341: 84, 1993.
13. MacNaul, K. L., and Hutchinson, N. I. Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle cells under normal and inflammatory conditions. Biochem. Biophys. Res. Commun. 196: 1330, 1993.
14. Cunha, F. Q., Assreuy, J., Moss, D. W., Rees, D., Leal, L. M., Moncada, S., Carrier, M., O'Donnell, C. A., and Liew, F. Y. Differential induction of nitric oxide synthase in various organs of the mouse during endotoxaemia: Role of TNF-alpha and IL-1-beta. Immunology 81: 211, 1994.
15. Bateson, A. N., Jakiwczyk, O. M., and Schulz, R. Rapid increase in inducible nitric oxide synthase gene expression in the heart during endotoxemia. Eur. J. Pharmacol. 303: 141, 1996.
16. Barthlen, W., Stadler, J., Lehn, N. L., Miethke, T., Bartels, H., and Siewert, J. R. Serum levels of end products of nitric oxide synthesis correlate positively with tumor necrosis factor alpha and negatively with body temperature in patients with postoperative abdominal sepsis. Shock 2: 398, 1994.
17. Kooy, N. W., Lewis, S. J., Royall, J. A., Ye, Y. Z., Kelly, D. R., and Beckman, J. S. Extensive tyrosine nitration in human myocardial inflammation: Evidence for the presence of peroxynitrite. Crit. Care Med. 25: 812, 1997.
18. Mathiak, G., Szewczyk, D., Abdullah, F., Ovadia, P., and Rabinovici, R. Platelet-activating factor (PAF) in experimental and clinical sepsis. Shock 7: 391, 1997.
19. Bone, R. C. Phospholipids and their inhibitors: A critical evaluation of their role in the treatment of sepsis. Crit. Care Med. 20: 884, 1992.
20. Szabo, C., Wu, C. C., Mitchell, J. A., Gross, S. S., Thiemermann, C., and Vane, J. R. Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ. Res. 73: 991, 1993.
21. MacMicking, J. D., North, R. J., La, C. R., Mudgett, J. S., Shah, S. K., and Nathan, C. F. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc. Natl. Acad. Sci. USA 94: 5243, 1997.
22. Girotra, N. N., Biftu, T., Ponpipom, M. M., Acton, J. J., Alberts, A. W., Bach, T. N., Ball, R. G., Bugianesi, R. L., Parsons, W. H., Chabala, J. C., Davies, P., Doebber, T. W., Doherty, J., Graham, D. W., Hwang, S.-B., Kuo, C. H., Lam, M.-H., Luell, S., MacIntyre, D. E., Meurer, R., Roberts, C. D., Sahoo, S. P., and Wu, M. S. Development, synthesis, and biological evaluation of (-)-trans-(2S,5S)-2-[3-[(2-oxopropyl)sulfonyl]-4-n-propoxy-5-(3-hydroxypropoxy) phenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran, a potent orally active platelet-activating factor (PAF) antagonist and its water-soluble prodrug phosphate ester. J. Med. Chem. 35: 3474, 1992.
23. Wallerson, D. C., Ganau, A., Roman, M. J., and Devereux, R. B. Measurement of cardiac output by M-mode and two-dimensional echocardiography: Application to patients with hypertension. Eur. Heart J. 11(Suppl. i): 67, 1990.
24. Pollick, C., Hale, S. L., and Kloner, R. A. Echocardiographic and cardiac doppler assessment of mice. J. Am. Soc. Echocardiogr. 8: 602, 1995.
25. Kass, D. A., Hare, J. M., and Georgakopoulos, D. Murine cardiac function: A cautionary tail. Circ. Res. 82: 519, 1998.
26. Iwase, M., Uechi, M., Vatner, D. E., Asai, K., Shannon, R. P., Kudej, R. K., Wagner, T. E., Wight, D. C., Patrick, T. A., Ishikawa, Y., Homcy, C. J., and Vatner, S. F. Cardiomyopathy induced by cardiac Gs alpha overexpression. Am. J. Physiol. 272: H585, 1997.
27. Siri, F. M., Jelicks, L. A., Leinwand, L. A., and Gardin, J. M. Gated magnetic resonance imaging of normal and hypertrophied murine hearts. Am. J. Physiol. 272: H2394, 1997.
28. Manning, W. J., Wei, J. Y., Katz, S. E., Litwin, S. E., and Douglas, P. S. In vivo assessment of LV mass in mice using high-frequency cardiac ultrasound: Necropsy validation. Am. J. Physiol. 266: H1672, 1994.
29. Gardin, J. M., Siri, F. M., Kitsis, R. N., Edwards, J. G., and Leinwand, L. A. Echocardiographic assessment of left ventricular mass and systolic function in mice. Circ. Res. 76: 907, 1995.
30. Hoit, B. D., Khoury, S. F., Kranias, E. G., Ball, N., and Walsh, R. A. In vivo echocardiographic detection of enhanced left ventricular function in gene-targeted mice with phospholamban deficiency. Circ. Res. 77: 632, 1995.
31. Krege, J. H., Hodgin, J. B., Hagaman, J. R., and Smithies, O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25: 1111, 1995.
32. James, J. F., Hewett, T. E., and Robbins, J. Cardiac physiology in transgenic mice. Circ. Res. 82: 407, 1998.
33. Ishii, S., Kuwaki, T., Nagase, T., Maki, K., Tashiro, F., Sunaga, S., Cao, W. H., Kume, K., Fukuchi, Y., Ikuta, K., Miyazaki, J., Kumada, M., and Shimizu, T. Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. J. Exp. Med. 187: 1779, 1998.
34. Wray, G. M., Millar, C. G., Hinds, C. J., and Thiemermann, C. Selective inhibition of the activity of inducible nitric oxide synthase prevents the circulatory failure, but not organ injury/ dysfunction, caused by endotoxin. Shock 9: 329, 1998.